Skip to main content

Table 2 Schedule of administration of the investigational product and combined drug/safety assessment

From: A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy

  1. CT computed tomography, HLA human leucocyte antigen, KPS Karnofsky Performance Status
  2. Required
  3. The data obtained before informed consent was signed may be used, if available